Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. [electronic resource]
Producer: 20171004Description: 1237-1243 p. digitalISSN:- 1526-632X
- Adult
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Calcitonin Gene-Related Peptide Receptor Antagonists
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Migraine Disorders -- prevention & control
- Outcome Assessment, Health Care
- Patient Reported Outcome Measures
No physical items for this record
Publication Type: Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article
There are no comments on this title.
Log in to your account to post a comment.